Mereo BioPharma Group Ownership | Who Owns Mereo BioPharma Group?


OverviewFinancialsChart

Mereo BioPharma Group Ownership Summary


Mereo BioPharma Group is owned by 14.13% institutional investors, 1.03% insiders, and 84.85% retail investors. Janus henderson group is the largest institutional shareholder, holding 2.22% of MREO shares. UBS (Lux) EF Biotech (USD) P-acc is the top mutual fund, with 0.55% of its assets in Mereo BioPharma Group shares.

MREO Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockMereo BioPharma Group14.13%1.03%84.85%
SectorHealthcare Stocks 57.47%9.40%33.13%
IndustryBiotech Stocks 69.06%8.93%22.01%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Janus henderson group17.12M2.22%$59.84M
Rubric capital management lp15.31M1.99%$53.58M
Rock springs capital management lp9.60M1.25%$33.60M
Adage capital partners gp8.72M1.13%$30.50M
Mangrove partners8.64M1.12%$30.23M
Deerfield management company, l.p. (series c)6.71M0.87%$23.49M
Frazier life sciences management4.40M0.63%$15.84M
Alkeon capital management4.70M0.61%$16.44M
683 capital management4.55M0.59%$15.93M
Millennium management3.97M0.51%$13.88M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tejara capital2.32M5.31%$8.11M
Mangrove partners8.64M3.34%$30.23M
Acuta capital partners779.31K2.74%$2.73B
Great point partners1.15M1.90%$4.03M
Clearline capital lp3.22M1.49%$11.26M
Rock springs capital management lp9.60M1.28%$33.60M
683 capital management4.55M0.99%$15.93M
Frazier life sciences management4.40M0.74%$15.84M
Rubric capital management lp15.31M0.69%$53.58M
Healthinvest partners ab390.00K0.65%$1.37M

Top Buyers

HolderShares% AssetsChange
Janus henderson group17.12M0.03%4.78M
Frazier life sciences management4.40M0.74%4.40M
Ubs group2.65M0.00%2.65M
Great point partners1.15M1.90%1.15M
Ubs asset management americas964.90K0.00%964.90K

Top Sellers

HolderShares% AssetsChange
Millennium management3.97M0.01%-1.43M
Morgan stanley207.74K0.00%-1.17M
Adage capital partners gp8.72M0.05%-1.00M
Price t rowe associates inc /md/---991.97K
Tejara capital2.32M5.31%-512.90K

New Positions

HolderShares% AssetsChangeValue
Frazier life sciences management4.40M0.74%4.40M$15.84M
Ubs group2.65M0.00%2.65M$9.27M
Great point partners1.15M1.90%1.15M$4.03M
Ubs asset management americas964.90K0.00%964.90K$3.38M
Woodline partners lp618.78K0.01%618.78K$2.17M

Sold Out

HolderChange
Plante moran financial advisors-48.00
Quadrant capital group-398.00
Tower research capital llc (trc)-645.00
Ica group wealth management-1.00K
Point72 asset management-1.90K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20249314.81%108,788,6352.89%140.30%3818.75%2623.81%
Sep 30, 202481-105,735,8605.18%6833.31%32-8.57%21-22.22%
Jun 30, 202480-4.76%100,517,09019.63%148870446.46%34-33.33%27125.00%
Mar 31, 20248425.37%84,026,0016.98%-0.00%5134.21%129.09%
Dec 31, 20236717.54%78,543,74611.37%651.91%38100.00%11-35.29%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
UBS (Lux) EF Biotech (USD) P-acc855.00K0.55%336.80K
HealthInvest Sustainable Healthcare E270.00K0.17%-
Tema Obesity & Cardiometabolic ETF267.46K0.17%-
Tema Oncology ETF261.68K0.17%-
iShares Genomics Immnlgy & Hlthcr ETF246.60K0.16%-
abrdn Life Sciences Investors160.38K0.10%160.38K
UBS Global Equity Biotech128.03K0.08%128.03K
HealthInvest Alpha Fund C120.00K0.08%120.00K
Alger LIfe Sciences Innovation Composite102.58K0.07%-84.07K
Fidelity Nasdaq Composite Index92.16K0.06%-

Recent Insider Transactions


DateNameRoleActivityValue
Sep 13, 2024Scots-Knight Denise Chief Executive OfficerSell$253.45K
Sep 12, 2024Scots-Knight Denise Chief Executive OfficerSell$127.97K
Sep 12, 2024Lewicki John A. Chief Scientific OfficerSell$23.31K
Sep 13, 2024Lewicki John A. Chief Scientific OfficerSell$46.17K
Sep 12, 2024Sermon Charles General CounselSell$44.64K

Insider Transactions Trends


DateBuySell
2025 Q1--
2024 Q3-13
2024 Q2-12
2024 Q1--

MREO Ownership FAQ


Who Owns Mereo BioPharma Group?

Mereo BioPharma Group shareholders are primarily institutional investors at 14.13%, followed by 1.03% insiders and 84.84% retail investors. The average institutional ownership in Mereo BioPharma Group's industry, Biotech Stocks , is 69.06%, which Mereo BioPharma Group falls below.

Who owns the most shares of Mereo BioPharma Group?

Mereo BioPharma Group’s largest shareholders are Janus henderson group (17.12M shares, 2.22%), Rubric capital management lp (15.31M shares, 1.99%), and Rock springs capital management lp (9.6M shares, 1.25%). Together, they hold 5.46% of Mereo BioPharma Group’s total shares outstanding.

Does Blackrock own Mereo BioPharma Group?

BlackRock is not among the top 10 institutional shareholders of Mereo BioPharma Group.

Who is Mereo BioPharma Group’s biggest shareholder by percentage of total assets invested?

Tejara capital is Mereo BioPharma Group’s biggest shareholder by percentage of total assets invested, with 5.31% of its assets in 2.32M Mereo BioPharma Group shares, valued at 8.11M$.

Who is the top mutual fund holder of Mereo BioPharma Group shares?

UBS (Lux) EF Biotech (USD) P-acc is the top mutual fund holder of Mereo BioPharma Group shares, with 0.55% of its total shares outstanding invested in 855K Mereo BioPharma Group shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools